Refine by
Stroke Patient Articles & Analysis
75 news found
FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022. ...
ByBayer AG
“Previous trials evaluating NOACs vs VKAs for stroke prevention in non-valvular atrial fibrillation have excluded patients with advanced chronic kidney disease. ...
ByBayer AG
Applying induced pluripotent stem cell (iPSC) technology, patient-cell derived 3D micro tissues exhibiting hereditary cardiac diseases are mass-produced in micro wells. ...
The day after the procedure, the patients were examined by magnetic resonance imaging for signs of small strokes triggered by the treatment and then followed up for one year. ...
With the potential to act as distinct option for the prevention of thrombosis and ischemic strokes, asundexian has projected peak sales of more than five billion euros. It is estimated that around 40 percent of eligible patients are either not treated with direct oral anticoagulants or undertreated as these patients assess the bleeding risk to be ...
ByBayer AG
Oodatroltide addresses the needs of more than 70% of acute ischemic stroke (AIS) patients who are either ineligible to receive proper therapy or are dissatisfied with the treatment outcome. The drug improves stroke treatment rates while expanding treatment coverage, providing neuroprotection, and reducing irreversible damage to the brain ...
The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification ...
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients ...
ByBayer AG
“As a cardiologist involved in patient care and research, this is a unique opportunity to save lives and improve outcomes with early, accurate cardiovascular disease detection,” said Villines. ...
ByElucid
TIGERTRIEVER 13 is the smallest revascularization device in the world to date and is designed to remove thrombus from delicate brain blood vessels during an ischemic stroke. It is the only device that adjusts to the vasculature and clot, a more atraumatic approach than existing devices. ...
New device presentation: IVS4 for Lower Limbs as a complementary approach to balance exercise, strengthening and robotic rehabilitation for gait recovery Lecture: Comparison of EEG biomarkers in Mirror Therapy and Video Therapy in normals and hemiplegic stroke patients – Dr ADHAM Ahmed from CHU St Etienne Poster: Videotherapy for rehabilitation after a ...
Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...
"Xarelto shows a significant benefit in patients with PAD who remain at high risk for major thrombotic events post lower extremity revascularization. ...
ByBayer AG
Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke. ...
Robot-assisted therapy (RAT) is of significant interest in early rehabilitation, when neuroplasticity is high but motor control is frequently insufficient for patients to independently practice functional movements. Many patients with stroke experience persistent upper limb (UL) impairments. This single-blind, randomized, controlled trial[i] ...
ByAxinesis
The surveillance data included in the submission represented real-world outcomes in 20,264 patients considered at standard surgical risk. Those data demonstrated that use of Silk Road Medical’s TCAR® system is statistically non-inferior in stroke and death outcomes to CEA, while showing a ninefold reduction in cranial nerve injury (CNI) (2.7% vs 0.3%, ...
While highly effective, these methods require specialized imaging suites that are critically in need by many other patients. The new PUMA-G system allows for feeding tube insertion at the patient’s bedside. The device uses a magnetic balloon that is fed through the patient’s mouth and guided through the stomach with an external ...
ByCoapTech
CINCINNATI, OH – March 30, 2022 – Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, has been selected to participate in the Mayo Clinic and Arizona State University MedTech Accelerator. ...
The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. ...
The briefing, titled "ReStore Soft Exo-Suit for gait rehabilitation" includes a description of the ReStore device, how it's used and why the technology is innovative for the treatment of patients during post-stroke gait training. The MIB also outlines a pathway to care using the technology and how much it costs. ...